US69404D1081 - Common Stock
PACIFIC BIOSCIENCES OF CALIF
NASDAQ:PACB (5/17/2024, 7:18:26 PM)
After market: 2.01 -0.01 (-0.5%)2.02
-0.17 (-7.76%)
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 769 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The firm has developed Single Molecule, Real-Time (SMRT) technology, which accurately detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid (DNA) molecules. The Company’s products include Revio, Sequel, Sequel II and Sequel IIe instruments that conduct, monitor, and analyze single-molecule biochemical reactions in real time. The instruments use extremely sensitive imaging systems to collect the light pulses emitted by fluorescent reagents allowing the observation of biological processes. Once sequencing is started, the real-time data is delivered to the system’s primary analysis pipeline, which outputs base identity and quality values.
PACIFIC BIOSCIENCES OF CALIF
1305 O'brien Drive
Menlo Park CALIFORNIA 94025
P: 16505218000
CEO: Christian O. Henry
Employees: 769
Website: https://www.pacb.com/
/PRNewswire/ --Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading...
PACB stock results show that Pacific Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pacific Biosciences (NASDAQ:PACB) just reported results for the first quarter o...
/PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024. First quarter results: Revenue of $38.8 million...
Investing with the Ark Invest guru is a roller coaster ride, but she always keeps her big ideas for the future in front of her.
/PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results...
Here you can normally see the latest stock twits on PACB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: